Results 1 to 10 of about 41,221 (142)

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population [PDF]

Advances in Pharmacological Sciences, 2013
Aminoglycoside dosing has been studied in the obese population, typically recommending an adjusted weight utilizing a 40% dosing weight correction factor (IBW + 0.4 × (TBW–IBW)).
Ashley L. Ross, Jennifer L. Tharp, Gerald R. Hobbs, Richard McKnight, Aaron Cumpston   +4 more
doaj   +5 more sources

Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort [PDF]

Neurology and Therapy, 2023
Introduction Natalizumab, a therapy for relapsing–remitting multiple sclerosis (RRMS), is associated with a risk of progressive multifocal leukoencephalopathy (PML). Over the last several years, practitioners have used off-label extended interval dosing (
Juliette Pelle, Anais R. Briant, Pierre Branger, Nathalie Derache, Charlotte Arnaud, Christine Lebrun-Frenay, Mikael Cohen, Lydiane Mondot, Jerome De Seze, Kevin Bigaut, Nicolas Collongues, Laurent Kremer, Damien Ricard, Flavie Bompaire, Charlotte Ohlmann, Magali Sallansonnet-Froment, Jonathan Ciron, Damien Biotti, Beatrice Pignolet, Jean-Jacques Parienti, Gilles Defer   +20 more
doaj   +2 more sources

Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis [PDF]

Journal of Neuroinflammation, 2023
Background Recent studies suggest that extended interval dosing of ocrelizumab, an anti-B cell therapy, does not affect its clinical effectiveness in most patients with multiple sclerosis (MS). However, it remains to be established whether certain B cell
Carla Rodriguez-Mogeda, Zoë Y. G. J. van Lierop, Susanne M. A. van der Pol, Loet Coenen, Laura Hogenboom, Alwin Kamermans, Ernesto Rodriguez, Jack van Horssen, Zoé L. E. van Kempen, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Maarten E. Witte, Joep Killestein, Helga E. de Vries   +13 more
doaj   +2 more sources

Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis [PDF]

Annals of Clinical and Translational Neurology
Objective We aimed to investigate the comparative effectiveness of standard versus personalized extended interval dosing of anti‐CD20 therapy on clinical and sub‐clinical outcomes in multiple sclerosis.
Nabil K. El Ayoubi, Fares Fahd, Hani Tamim, Salem Hannoun, Mark Bal, Elham El‐Hallak, Samia J. Khoury   +6 more
doaj   +2 more sources

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022
Background: Cognitive impairment and neuropsychiatric symptoms are frequently reported in Relapsing-Remitting Multiple Sclerosis (RRMS). Natalizumab (NTZ) is usually administered on a 4-weekly Standard Interval Dosing (SID) schedule.
Eileen J. McManus, Karen M. Clark, Christopher Frampton, Jamie A.B. Macniven, Jan Schepel   +4 more
doaj   +2 more sources

Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: A 96-week follow-up pilot study [PDF]

Frontiers in Immunology, 2023
We aimed to assess the long-term safety and effectiveness of ocrelizumab in a cohort of patients with multiple sclerosis (MS) at high risk of progressive multifocal leukoencephalopathy (PML), previously treated with natalizumab in extending interval ...
Pilar Santiago-Setien, Cristina Barquín-Rego, Paula Hernández-Martínez, María Ezquerra-Marigomez, Marta Torres-Barquin, Cristina Menéndez-Garcia, Fernando Uriarte, Yésica Jiménez-López, Mercedes Misiego, Jose Ramón Sánchez de la Torre, Sonia Setien, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado, Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho   +16 more
doaj   +2 more sources

Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study [PDF]

Frontiers in Immunology, 2021
The extended interval dosing (EID) of natalizumab has been suggested to be associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) and short-term preservation of efficacy but its long-term effectiveness remain unknown. We aimed
Javier Riancho, Javier Riancho, Javier Riancho, Javier Riancho, Sonia Setien, Jose Ramón Sánchez de la Torre, Marta Torres-Barquin, Mercedes Misiego, José Luis Pérez, Tamara Castillo-Triviño, Tamara Castillo-Triviño, Cristina Menéndez-García, Manuel Delgado-Alvarado, Manuel Delgado-Alvarado   +13 more
doaj   +2 more sources

Optimizing gentamicin conventional and extended interval dosing in neonates using Monte Carlo simulation – a retrospective study [PDF]

BMC Pediatrics, 2019
Background Although aminoglycosides are routinely used in neonates, controversy exists regarding empiric dosing regimens. The objectives were to determine gentamicin pharmacokinetics in neonates, and develop initial mg/kg dosing recommendations that ...
Monique Bergenwall, Sandra A. N. Walker, Marion Elligsen, Dolores C. Iaboni, Carla Findlater, Winnie Seto, Eugene Ng   +6 more
doaj   +2 more sources

Extended interval dosing of natalizumab: a two-center, 7-year experience [PDF]

Therapeutic Advances in Neurological Disorders, 2014
Background: The enthusiasm for natalizumab, a highly efficacious agent in the treatment of multiple sclerosis (MS), has been tempered by the risks of progressive multifocal leukoencephalopathy associated with its use, and strategies to minimize those ...
Roberto Bomprezzi, Siddharama Pawate
doaj   +2 more sources

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic? [PDF]

Frontiers in Oncology, 2020
Patients with lung cancer are particularly vulnerable to complications from coronavirus disease-2019 (COVID-19). Recurrent hospital visits and hospital admission are potential risk factors for acquiring infection with its causative pathogen, severe acute
Kartik Sehgal, Kartik Sehgal, Daniel B. Costa, Deepa Rangachari   +3 more
doaj   +2 more sources